Keywords: aFVII; activated FVII; AHA; acquired hemophilia A; anti-hFVIII; anti-human FVIII; aPCC; activated prothrombin complex concentrate; aPTT; activated partial thromboplastin time; AT; antithrombin; AUC; area under the curve; BPA; bypassing agent; BU; Bethesda
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: VTE; venous thromboembolism; HSCT; hematopoietic stem cell transplant; LMWH; low molecular weight heparin; IMIDs; immunomodulatory drugs; AML; acute myeloid leukemia; IQR; interquartile range; TAT; thrombin antithrombin; FVII; factor VII; FVIII; factor VI
Keywords: ADP; adenosine diphosphate; APC; activated protein C; AT-III; antithrombin III; ATP; adenosine triphosphate; cAMP; cyclic adenosine monophosphate; CLP; cecal ligation - perforation; DIC; disseminated intravascular coagulation; LPS; lipopolysaccharide; IL-
Keywords: aCL; anticardiolipin; ADP; adenosine diphosphate; APOH; apolipoprotein H; APS; antiphospholipid syndrome; β2GPI; β2-glycoprotein I; DVT; deep vein thrombosis; FDR; false discovery rate; GO; gene ontology; IL; interleukin; IRAK 1; interleukin-1 receptor-
Keywords: AASVV; ANCA associated small vessel vasculitis; APS; antiphospholipid antibody syndrome; CAD; coronary artery disease; cfDNA; cell-free deoxyribonucleic acid; citH3; citrullinated histone 3; CD; Crohn's disease; DPI; diphenylene iodonium; DNA; deoxyribonu
Keywords: A2Ms; α-2- macroglobulins; AFLEI; elastase inhibitor from Aspergillus flavus; AFUEI; elastase inhibitor from Aspergillus fumigatus; AP; α-2-antiplasmin; AT; antithrombin; bFGF; basic fibroblast growth factor; BSuPI; Bacillus subtilis protease inhibitor;
Keywords: Blood coagulation; Tissue factor; Thrombin; Platelets; Protease-activated receptors; Metastasis; AT; antithrombin; BMI; body mass index; CA-125; cancer antigen 125; CCC; clear cell carcinoma; CD; cluster of differentiation; CG; control group; DVT; deep ve
Keywords: aPTT; activated partial thromboplastin time; AT; antithrombin; CAT; calibrated automated thrombography; ETP; endogenous thrombin potential; F1Â +Â 2; prothrombin fragments F1Â +Â 2; FII; prothrombin; FVIII:C; factor VIII coagulant activity; IDDM; insulin-
Keywords: VTE; (venous thromboembolism); ATE; (arterial embolism and thrombosis); COCs; (combined oral contraceptives); PMDA; (Pharmaceuticals and Medical Devices Agency); TFPI; (tissue factor pathway inhibitor); LEP; (low dose estrogen progestin); MHLW; (Ministry
Keywords: Hemostasis; Fucoidan; Hemophilia; NMR; Structure; Screening; NASP; non-anticoagulant sulfated polysaccharide; TFPI; tissue factor pathway inhibitor; TF; tissue factor; s.c.; subcutaneous; p.o.; per os (oral); Mw; molecular weight; polyD; polydispersity; O
Keywords: PUC; Premature uterine contractions; PPROM; Preterm premature rupture of membranes; PTL; Preterm labor; aPTT; Activated partial thromboplastin time; PT; Prothrombin time; PT F1Â +Â 2; Prothrombin Fragments F1Â +Â 2; TAT; Thrombin anti thrombin; PAI 1; Pla
Keywords: OC; Oral contraceptives; DRSP-OC; drospirenone-containing oral contraceptives; APC; activated protein C; TFPI; tissue factor pathway inhibitor; SHBG; sex-hormone-binding globulin; ETP-APC and ETP+Â APC respectively; the endogenous thrombin potential in th
Keywords: CPB; cardiopulmonary bypass; TG; thrombin generation; CAT; calibrated automated thrombography; TFPI; tissue factor pathway inhibitor; AT; antithrombin; CABG; coronary artery bypass grafting; ACT; activated clotting time; UFH; unfractionated heparin; PPP;
Keywords: Avascular necrosis; Heparanase; TFPI;
Keywords: AT; antithrombin; AZ; AstraZeneca; CAT; calibrated automated thrombogram; ETP; endogenous thrombin potential; LT; lag time; HTS; high-throughput screening; PPP; platelet poor plasma; PRP; platelet rich plasma; RU; resonance units; SPR; surface plasmon res
Antibodies against TFPI and protein C are associated with a severe thrombotic phenotype in patients with and without antiphospholipid syndrome
Keywords: Antiphospholipid syndrome; TFPI; Antibodies; Protein C; Thrombosis;
Anti-haemostatic compounds from the vampire snail Cumia reticulata: Molecular cloning and in-silico structure-function analysis
Keywords: NGS; Next generation sequencing; RNA-Seq; RNA sequencing; ShKT; ShK toxin; SmCI; Sabellastarte magnifica Carboxypeptidase inhibitor; TFPI; tissue factor pathway inhibitor; vWFA; Von Willebrand factor A domain; Mollusc; Anti-haemostatic compounds; Protein
Comparative Effectiveness of Enoxaparin vs Dalteparin for Thromboprophylaxis After Traumatic Injury
Keywords: comparative effectiveness; dalteparin; enoxaparin; prophylaxis; trauma; VTE; DID; difference-in-differences; LMWH; low-molecular-weight heparin; PE; pulmonary embolism; PTSF; Pennsylvania Trauma System Foundation; RR; rate ratio; SDF; standardized differe
Full Length ArticleA novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7
Keywords: Blood coagulation; Hypoxia; HIF-2α; EPAS1; TFPI;
Tissue factor pathway inhibitor attenuates ER stress-induced inflammation in human M2-polarized macrophages
Keywords: TFPI; Cholesterol crystals; ER stress; Macrophages; Carotid endarterectomies; Inflammation; CC; cholesterol crystals; CHOP; CCAAT/enhancer-binding protein homologous protein; ER; endoplasmic reticulum; MDMs; monocyte-derived macrophages; PBA; 4-phenylbuty
Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration
Keywords: TFPI; Nonmem; Haemophilia; TMDD; Concizumab; mAb 2021
Regular articleOestrogen induced downregulation of TFPI expression is mediated by ERα
Keywords: ERα/β; Oestrogen rceptor alpha/beta; TFPI; Tissue factor pathway inhibitor; TF; tissue factor; E2; 17-β-oestradiol; EE2; 17-β-ethinyloestradiol; FUL; fulvestrant; CHX; cycloheximide; ERE; oestrogen response element; HRT; hormone replacement therapy; P
New observations on procoagulant properties of amniotic fluid: Microparticles (MPs) and tissue factor-bearing MPs (MPs-TF), comparison with maternal blood plasma
Keywords: MPs; microparticles; AF; amniotic fluid; TF; tissue factor; MPs-TF; tissue factor bearing MPs; TFPI; tissue factor pathway inhibitor; PS; phosphatidylserine; Microparticles; Amniotic fluid; Tissue factor; Tissue factor pathway inhibitor;
Maternal familial hypercholesterolaemia (FH) confers altered haemostatic profile in offspring with and without FH
Keywords: Apo; apolipoprotein; BMI; body mass index; CV; coefficient of variation; CVD; cardiovascular disease; ELISA; enzyme-linked immunosorbant assay; F1Â +Â 2; protrombin fragment 1Â +Â 2; FH; familial hypercholesterolaemia; LDL; low density lipoprotein; PAI-1;
Tissue factor pathway inhibitor prevents airway obstruction, respiratory failure and death due to sulfur mustard analog inhalation
Keywords: Sulfur mustard; Inhalation; Lung injury; TFPI; Airway; Coagulation
Tissue factor/TFPI and blood cells
Keywords: Tissue factor; TFPI; platelets; microparticles; neutrophils; monocytes
Protein Z/protein Z-dependent protease inhibitor system in human non-small-cell lung cancer tissue
Keywords: ABC; avidin - biotin complex technique; antibody T2G1; antibody directed to fibrin II (des fibrinopeptide B fibrin); antibody 1-8C6; antibody which reacts with fibrinogen or des fibrinopeptide A fibrin but not with des fibrinopeptide B fibrin; AT; antit
Assembly of the prothrombinase complex on the surface of human foreskin fibroblasts: Implications for connective tissue growth factor
Keywords: FXa; activated factor X; CTGF/CCN2; connective tissue growth factor; TF; tissue factor; TSP1; thrombospondin-1; HFF; human foreskin fibroblasts; FVII; factor VII; FX; factor X; FV; factor V; II; prothrombin; TGFβ; transforming growth factor beta; TGFβRI
Increased heparanase level and procoagulant activity in orthopedic surgery patients receiving prophylactic dose of enoxaparin
Keywords: DVT; deep vein thrombosis; HS; heparan sulfate; TF; tissue factor; TFPI; tissue factor pathway inhibitor; PE; pulmonary emboli; TAT; thrombin-antithrombin; PAI; plasminogen activator inhibitor; LMWH; low molecular weight heparin; TPA; tissue plasminogen a
Global haemostasis assays, from bench to bedside
Keywords: α; angle that assesses rate of clot formation; α2M; α2-macroglobulin; AMC; 7-amino-4-methylcoumarine; AT; antithrombin; AUC; area under the curve; APC; activated protein C; aPTT; activated partial thromboplastin time; A10; the amplitude after ten minut
New recommendations for thromboelastography reference ranges for pregnant women
Keywords: AA; alpha angle; CI; Coagulation index; GUH; General University Hospital; k; time k; LY60; fibrinolysis at 60 minutes; MA; maximum amplitude; r; time r; SD; standard deviation; TEG; thrombelastography; TFPI; tissue factor-pathway inhibitor; Thromboelastog
Activation of coagulation in amniotic fluid during normal human pregnancy
Keywords: Amniotic fluid; Normal pregnancy; Tissue factor; TFPI; D-dimer; Prothrombin factor 1 + 2; F1 + 2; FX activation
An assay to evaluate heparanase procoagulant activity
Keywords: TF; tissue factor; TFPI; tissue factor pathway inhibitor; HS; heparan sulfate; CS; cesarean section; IUGR; intrauterine growth restriction; PGE2; prostaglandin E2; Heparanase; Tissue factor; Coagulation; Pregnancy;
Leptin and resistin induce increased procoagulability in diabetes mellitus
Keywords: DM; diabetes mellitus; DMSO; dimethyl sulfoxide; FVIIa; factor VIIa; FX; factor X; HUVECs; human umbilical endothelial cells; PAI; plasminogen activator inhibitor 1; SD; standard deviation; SEM; standard error of the mean; TF; tissue factor; TFPI; tissue
Heparin affinity of factor VIIa: Implications on the physiological inhibition by antithrombin and clearance of recombinant factor VIIa
Keywords: FVIIa; Factor VIIa; TF; Tissue Factor; rFVIIa; recombinant FVIIa; LMWH; Low molecular weight heparin; UHF; Unfractionated heparin; SPR; Surface Plasmon resonance; TFPI; Tissue factor pathway inhibitor; RU; Response units;
TFPI or uPA–PAI-1 complex affect cell function through expression variation of type II very low density lipoprotein receptor
Keywords: VLDLR; Subtype; TFPI; uPA–PAI-1; β-Catenin
Functional characterization of polymorphisms in the human TFPI gene
Keywords: TFPI; Polymorphisms; Reporter gene; EMSA;
Coagulation-Fibrinolysis Changes During Off-Pump Bypass: Effect of Two Heparin Doses
Keywords: ACT; activated clotting time; CABG; coronary artery bypass graft surgery; CPB; cardiopulmonary bypass; F1+2; prothrombin fragment 1+2; OPCABG; off-pump coronary artery bypass graft surgery; PAP; plasmin-antiplasmin complex; PFA; platelet function analyzer
Plasma factor and inhibitor composition contributes to thrombin generation dynamics in patients with acute or previous cerebrovascular events
Keywords: AT; antithrombin; AUC; area under the curve; CRP; C-reactive protein; CT; computed tomography; F; factor; IL-6; interleukin-6; LDL; low density lipoprotein; MaxL; maximum level of thrombin production; MaxR; maximum level of thrombin production; MRI; magne
Porphyromonas gingivalis infection and prothrombotic effects in human aortic smooth muscle cells
Keywords: VSMC; vascular smooth muscle cells; HAEC; human aortic endothelial cells; HASMC; human aortic smooth muscle cells; TF; tissue factor; TFPI; tissue factor pathway inhibitor; LPS; lipopolysacharide; LDH; lactate dehydrogenase; Infection; Periodontitis; P. g
Expression of the V264M TFPI mutant in endothelial cell cultures may involve mRNA stability
Keywords: TF; tissue factor; TFPI; tissue factor pathway inhibitor; CAT; chloramphenicol acetyltransferase; HCAEC; human coronary artery endothelial cells.; Endothelial cells; Expression; mRNA; Stability; Mutant; TFPI;
Long term administration of LMWH - pharmacodynamic parameters under therapeutic or prophylactic regimen of enoxaparin or tinzaparin in neurological rehabilitation patients
Keywords: Enoxaparin; Tinzaparin; TFPI; D-dimer; Anti-FXa-activity; cohort study;
Peptide corresponding to the C terminus of tissue factor pathway inhibitor inhibits mesangial cell proliferation and activation in vivo
Keywords: Anti-proliferation; Apoptosis; C terminus; Mesangial cell; Proliferative glomerulonephritis; TFPI;
Platelet aggregation and thrombosis in xenotransplantation between pigs and humans
Keywords: HXR; hyperacute rejection; DXR; delayed xenograft rejection; TFPI; tissue factor pathway inhibitor; fgl2; fibrinogen-like protein 2; vWF; von Willebrand factor; IC; immune complexes; PBMC; peripheral blood mononuclear cell; PBPC; peripheral blood progenit
Differences in circadian variations of tissue factor pathway inhibitor type 1 between able-bodied and spinal cord injured
Keywords: TFPI; Tissue factor pathway inhibitor; FXa; Activated factor X; LDL; Low density lipoprotein; HDL; High density lipoprotein; VLDL; Very low density lipoprotein; TG; Triglycerides; OC; Oral contraceptives; HRT; Hormone replacement therapy; PAI-1; Plasminog
Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease
Keywords: ACS; acute coronary syndromes; aPTT; activated partial thromboplastin time; Asp189; aspartic acid residue; CAD; coronary artery disease; EDTA; ethylenediaminetetraacetic acid; EPR-1; effector cell protease receptor-1; F; factor; F1.2; fragment 1.2; FEU; f
Pharmacological Therapy for Acute Respiratory Distress Syndrome
Keywords: APC; activated protein C; ARDS; acute respiratory distress syndrome; BAL; bronchoalveolar lavage; FiO2; fraction of inspired oxygen; IL; interleukin; KGF; keratinocyte growth factor; NF-κB; nuclear factor-κB; PAI-1; plasminogen activator inhibitor 1; Pa
Estatinas y ácidos grasos omega-3. Disminución de la mortalidad cardiovascular dependiente e independiente de la reducción de la colesterolemia
Keywords: Ácidos grasos omega-3; Estatinas; Hipercolesterolemia; Efectos pleiotrópicos; Estudios clÃnicos; Omega-3 fatty acids; Statins; Hypercholesterolemia; Pleiotropic effects; Clinical trials; AGPI; ácidos grasos poliinsaturados; ALA; ácido alfalinolénico